Scorr-Insert
X

Find Approved Dermatology Drugs in Clinical Development in UNITED STATES

A collaboration with SCORR Marketing

Loading...

All Data

Filters Filter refresh
×
FILTER DATA :
News Type filter
    Company filter
      Product Type filter
        Deal Size filter
          Upfront Payment filter
            refresh

            Product Type Full Screen

            Companies Full Screen

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Apremilast

            Therapeutic Area: Dermatology

            Highest Development Status: Approved Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable May 06, 2020

            Details:

            Oral Otezla 30 mg twice daily achieved a statistically significant improvement, compared with placebo in mild-to-moderate Psoriasis.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Aminolevulinic Acid

            Therapeutic Area: Dermatology

            Highest Development Status: Approved Product Type: Small molecule

            Partner/Sponsor/Collaborator: Maruho Co, Ltd

            Deal Size: Undisclosed Upfront Cash: $6.4 million

            Deal Type: Licensing Agreement April 20, 2020

            Details:

            Maruho will obtain exclusive development and commercialization rights including the right to sublicense for Ameluz® in Asia, Australia, New Zealand.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Sarecycline

            Therapeutic Area: Dermatology

            Highest Development Status: Approved Product Type: Small molecule

            Partner/Sponsor/Collaborator: ALMIRALL

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Licensing Agreement February 24, 2020

            Details:

            Almirall plans to develop sarecycline for acne in China, with a potential submission to the China National Medical Products Administration in 2023.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Trifarotene

            Therapeutic Area: Dermatology

            Highest Development Status: Approved Product Type: Small molecule

            Partner/Sponsor/Collaborator: Galderma

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Partnership January 08, 2020

            Details:

            Certara's Simcyp population-based Simulator was used to support Galderma’s successful U.S. FDA new drug application for AKLIEF (trifarotene) Cream, 0.005% for the topical treatment of acne.